Finance Watch: Biopharma IPO Market Silence Continues In The US
Three Potential Offerings, Including Two Micro-Caps, Recently Filed
Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.
